Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.

Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response ...

Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree with the ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “With this FDA decision, Dupixent is now approved for seven ...

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...